ArticleInternational journal of general medicine2025
The Role of miR-30d-5p in Neutrophil-Derived Exosomes in Promoting Systemic Lupus Erythematosus.
Article in International journal of general medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Neutrophil Secretory Proteins Inhibit Calcium Oxalate Crystallisation and Crystal Growth, but Promote Crystal Aggregation.Immunology · 2026Article
- The Mechanistic Review of the Molecular Interface of RNA-Loaded Extracellular Vesicles: Redefining Targeted Therapy for Autoimmune Disorders.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In this study, we investigated the role of neutrophil-derived exosomal miR-30d-5p in systemic lupus erythematosus (SLE). Methods: We extracted exosomes from the neutrophils collected from SLE patients and healthy donors and analyzed the relative level of miR-30d-5p. The exosomes were characterized by transmission electron microscopy (TEM) and nanoparticle tracking analysis (NTA). We mimicked SLE using MRL/lpr mice and treated the mice with exosomes and miR-30d-5p inhibitors. The RNA level of miR-30d-5p in serum of mice was analyzed by qPCR. The images of spleen were captured to evaluate splenomegaly. The serum levels of anti-nuclear antibodies (ANAs), total IgG, total IgM, and anti-dsDNA IgG were measured by ELISA. The kidney injury was analyzed by albumin level, haematoxylin and eosin (HE) staining, active index, and chronic index. The T cell differentiation and B cell activation were detected by flow cytometry. For T follicular helper (TfH) cell analysis, cells were stained with anti-CXCR5 and anti-PD-1 antibodies. Levels of inflammatory cytokines in serum were measured by ELISA. Results: The exosomes from SLE patients showed significant higher level of miR-30d-5p. Treatment with neutrophil-exosomes enhanced the degree of splenomegaly in MRL/lpr mice and production of anti-nuclear antibodies (ANAs), total IgG, total IgM, and anti-dsDNA IgG, which was repressed by miR-30d-5p inhibitor. Compared with MRL/lpr mice, mice treated with neutrophil-derive exosomes exhibited a notable increase of proteinuria and infiltration of lymphocytes in kidney, whereas inhibition of miR-30d-5p reduced this elevation. Exosome treatment elevated the number of IL17+ Th17 cells, CXCR5+PD-1+ TfH cells, reduced the portion of Foxp3+ Treg cells, and elevated B cells, and inhibition of miR-30d-5p reversed these effects. Conclusion: The neutrophils from SLE exhibited higher level of miR-30d-5p, and inhibition of miR-30d-5p could suppress the T cell and B cell activation, reduce inflammatory cytokine and antibodies production, and alleviate the lupus nephritis during SLE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.